Presence in key European markets
Founded in 2006 in Croatia as a niche regional CRO, Optimapharm has successfully acquired and integrated several acquisitions across Europe in recent years. This external growth significantly strengthened Optimapharm presence in key European markets in Western and Northern Europe and expanded its in-house capabilities, for the benefit of its biopharmaceutical clients worldwide.
Excellence in recuing studies
Optimapharm today comprises over 400 employees, offering resources and expertise to its clients to conducts phase I – IV studies in all therapeutic areas with strong experience in Oncology, Neurosciences, Cardio-endocrinology-metabolic and Infectious diseases. With very strong operational teams, Optimapharm has also a reputation for excellence in rescuing studies.
Unrivalled access to emerging European markets
Operating through 24 offices in 35 European countries and Israel, Optimapharm offers unrivalled access to patients and Investigators in the emerging markets of Eastern and central Europe and Baltic Region, covering markets with a total population of over 500 million people.
Optimapharm’s key differentiators are its track record of delivery excellence at the highest industry standards, committed and stable project teams and a customer-focused approach that has led to over 95% repeat business. These differentiators enable Optimapharm to offer cost-effective clinical development solutions.
Moving forward, Optimapharm will continue to pursue a growth strategy supported by The Rohatyn Group (“TRG”), an emerging markets focused asset management firm, to capitalize on the expanding clinical research market through the combination of organic growth and targeted investments into complementary organizations. Optimapharm is committed to identifying and realizing market opportunities to best support its clients, employees, and growth as an organization.